Using modified immune cells to target ovarian cancer
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
This study is testing a new way to treat ovarian cancer by using your own immune cells to target a specific protein found in many ovarian cancer cases, and it's designed for patients whose cancer has come back and who have high levels of this protein.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10828349 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for ovarian cancer by using CAR T cells that are specifically designed to target a protein called folate receptor-alpha, which is found in a high percentage of ovarian cancer cases. The approach involves taking a patient's own immune cells, modifying them in the lab to recognize and attack cancer cells, and then reintroducing them into the patient's body. The study aims to assess the safety and effectiveness of this treatment in patients with recurrent ovarian cancer who have high levels of this protein. By exploring this innovative therapy, the research seeks to provide a new option for patients who have limited treatment choices.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with recurrent ovarian cancer who express high levels of folate receptor-alpha.
Not a fit: Patients without recurrent ovarian cancer or those whose tumors do not express folate receptor-alpha may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for patients with recurrent ovarian cancer.
How similar studies have performed: Previous research has shown promising results with CAR T cell therapies in other cancers, indicating potential for success in this novel application.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Powell, Daniel J. — University of Pennsylvania
- Study coordinator: Powell, Daniel J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.